TY - JOUR
T1 - Cancer and Immune System
T2 - Basic Concepts and Targets for Intervention
AU - Pardoll, Drew
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - A number of consensuses regarding cancer immunology have recently emerged from both preclinical immunorapy models and analysis of cancer patients. First and foremost, natural state of endogenous tumor reactive T cells is characterized by general hyporesponsiveness or anergy. This is likely due to a number of mechanisms that tumors use to induce tolerance as y develop. While many of newer generation vaccines can effectively transfer antigen to and activate dendritic cells, T-cell tolerance remains a major barrier that is difficult to overcome by vaccination alone. Preclinical models demonstrate that for poorly immunogenic tumors, once tolerance has been established, rapeutic vaccines alone are ineffective at curing animals with a significant established tumor burden. However, combination strategies of vaccination toger with inhibitors of immunologic checkpoints and agonists for co-stimulatory pathways are proving capable of overcoming tolerance and generating significant anti-tumor responses even in cases of established metastatic cancer.
AB - A number of consensuses regarding cancer immunology have recently emerged from both preclinical immunorapy models and analysis of cancer patients. First and foremost, natural state of endogenous tumor reactive T cells is characterized by general hyporesponsiveness or anergy. This is likely due to a number of mechanisms that tumors use to induce tolerance as y develop. While many of newer generation vaccines can effectively transfer antigen to and activate dendritic cells, T-cell tolerance remains a major barrier that is difficult to overcome by vaccination alone. Preclinical models demonstrate that for poorly immunogenic tumors, once tolerance has been established, rapeutic vaccines alone are ineffective at curing animals with a significant established tumor burden. However, combination strategies of vaccination toger with inhibitors of immunologic checkpoints and agonists for co-stimulatory pathways are proving capable of overcoming tolerance and generating significant anti-tumor responses even in cases of established metastatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=84940379785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940379785&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2015.05.003
DO - 10.1053/j.seminoncol.2015.05.003
M3 - Review article
C2 - 26320058
AN - SCOPUS:84940379785
SN - 0093-7754
VL - 42
SP - 523
EP - 538
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 4
ER -